Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

Overview of attention for article published in Frontiers in Neurology, June 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

twitter: 9 X users

Citations

dimensions_citation: 228 Dimensions

Readers on

mendeley: 273 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder

Cited by Canadian Agency for Drugs and Technologies in Health on 25 Feb 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.